Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Adults With Opioid Use Disorder Maintained on Buprenorphine/Naloxone
NCT04161066Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in opioid use disorder (OUD), sponsored by University of Wisconsin–Madison. Primary endpoints: Adverse Events at 5 weeks, Clinical Opiate Withdrawal Scale at 5 weeks and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
psilocybin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04161066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161066.